Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cerevel Therapeutics Holdings Inc

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 NORTH CHICAGO, Ill. , Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).

AbbVie Completes Acquisition of Cerevel Therapeutics

Abbott Labs

Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to be a great long-term investment. Kenvue and Sila Realty Trust are two newly-listed companies that could potentially reward investors similarly to AbbVie.

2 Stocks With Potential To Become Great Long-Term Investments

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ASML Hld

Domino's Pizza

Netflix

Taiwan Semiconductor Manufacturing

Visa

Understanding companies' fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages.

7 Stocks Set for a Major Bull Run

Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate.

3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle

AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader range of treatments has more than paid off.

AbbVie Analysts Lead the Stock Higher as Humira Worries Recede

Atmos Energy

Essex Property Trust

Realty Income Corp

Target

24/7 Insights Dividend Aristocrat shareholders could see some big upside in August.

5 Dividend Aristocrats May Be Primed for a Big August

Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024 Members receive an exclusive gift card offer and a chance to win $10,000* IRVINE, Calif. , July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21.

Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day

Amgen

AstraZeneca

Bristol-Myers

Johnson & Johnson

Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.

Pharma companies less concerned after hearing from US on negotiated prices for Medicare

On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the three months ended June 30, 2024, an increase of 55.8% year-on-year. On the other hand, sales of Elahere, a targeted anticancer drug, amounted to $128 million in the second quarter of 2024, increasing by 65.4% year-on-year.

AbbVie: Growth Is Still A Better Choice

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.

3 High-Yield Dividend Stocks That Are Looking Super Hot

AbbVie's recent Q2 earnings release was robust, validating my initial bullish thesis, which has aged well as the stock has outperformed the broader market since mid-April. The Q2 earnings release strengthened my bullish stance due to the robust performance across all business lines, solid operating leverage, and immense momentum in AbbVie's flagship products. According to my valuation analysis, ABBV stock is still around 35% undervalued.

AbbVie: Q2 Earnings Validate Bullish Case

On Thursday, AbbVie Inc.  ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.

AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and COMMAND maintenance trial2 In both trials, SKYRIZI achieved the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including mucosal healing** and histologic endoscopic mucosal healing †, 1 , 2 NORTH CHICAGO, Ill. , July 26, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.3 "Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief," said Edouard Louis, M.D.

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

The pharmaceutical sector mainstay posted a mixed second quarter. It topped analyst expectations for revenue and missed those for profitability, but investors were more focused on the future.

Why AbbVie Stock Was Cruising Higher on Thursday

AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Humira sales.

AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

AbbVie (NYSE: ABBV ) stock is the top trending ticker on Yahoo Finance on Thursday as investors are pumped up about news from the pharmaceutical company's latest earnings report. AbbVie started its earnings report for Q2 with adjusted EPS of $2.65.

AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs

AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago.

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

AbbVie stock slipped Thursday despite a second-quarter beat that included strong Skyrizi sales and a boost to 2024 earnings guidance.

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance

AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.

AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.

AbbVie lost its CEO last year even as its most important drug experienced a patent cliff. However, the company's business remains robust thanks to a deep lineup and rich pipeline.

News for AbbVie Stock (ABBV)